Dr. Raza Bokhari, former CEO of FSD Pharma, reports

DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLION

Attorneys for Dr. Raza Bokhari, the former chief executive officer and executive chairman of FSD Pharma Inc., have filed two new claims against his former employer.

The two matters filed with the Ontario Superior Court of Justice seek damages from FSD Pharma alleging breach of his employment contract, and for tortious and intentional interference with economic relations during and subsequent to Bokhari's tenure as FSD's executive chairman and CEO. The filings further claim negligence, misrepresentation and other causes on the part of FSD's founders, Anthony Durkacz and Zeeshan Saeed, before, during and after the proxy fight that ultimately led to his constructive dismissal in 2021. This proxy fight originated when Dr. Bokhari opposed Mr. Durkacz and Mr. Saeed's demands to acquire Lucid Psycheceuticals Inc., a shell company without any clinical-stage products in which Mr. Durkacz had a significant financial interest, which he initially did not fully disclose.

Dr. Bokhari already has an existing application before the Ontario Superior Court of Justice, seeking to set aside the arbitral award issued by arbitrator J. Douglas Cunningham in November, 2022. Dr. Bokhari, amongst other things, asserts that (a) neither the honorable Justice Cunningham, the arbitrator overseeing his wrongful dismissal matter, nor FSD Pharma's attorneys, Blake, Cassels & Graydon LLP, disclosed past and continuing business relationships between themselves. This non-disclosure, if true, appears to be a material violation of Section 11 of the Ontario Arbitration Act of 1991, giving rise to a reasonable apprehension of bias against Dr. Bokhari.

"Blake makes a claim on their website that they are 'adept at selecting the right arbitrators'," said Dr. Bokhari.

In addition to these disputes outlined above, FSD Pharma was recently sued for $53,047,000 by GBB Drink Lab in United States District Court, district of Florida, for misappropriating trade secrets and breaching non-disclosure agreements. The claim relates to alleged actions engaged in by Mr. Saeed, Mr. Durkacz and others at FSD Pharma, after Dr. Bokhari's departure from the company.

About Dr. Bokhari

A recipient of Philadelphia Business Journal's 40 under 40 award, Dr. Bokhari has developed outstanding expertise in aggregating and accelerating life sciences, health care services and pharmaceutical R&D (research and development) companies.

Dr. Bokhari is the managing partner of RBx Capital LP, and is nominated as the executive chairman and CEO of Medicus Pharma Ltd., a biotech company developing innovative and non-invasive therapies to treat cancerous melanomas. The company is expected to begin trading on Toronto Stock Exchange (TSX Venture Exchange).

For more information on Dr. Bokhari, including the complete story of his tenure at FSD Pharma, please visit his website.